Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 3561

  • Sort by Relevance to quickly find articles that most closely match your query.
1.
2.

Outcome of acute severe ulcerative colitis in patients previously exposed to immunosuppressive therapy.

Deiana S, Bagnoli S, Manetti N, Caini S, Giannotta M, Scaringi S, Annese V.

Dig Liver Dis. 2016 Aug 1. pii: S1590-8658(16)30531-X. doi: 10.1016/j.dld.2016.07.021. [Epub ahead of print]

PMID:
27553087
3.

Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Abdominal Operations for Inflammatory Bowel Disease.

Lightner AL, Raffals LE, Mathis KL, Cima RR, Tse CS, Pemberton JH, Dozois EJ, Loftus EV Jr.

J Crohns Colitis. 2016 Aug 19. pii: jjw147. [Epub ahead of print]

PMID:
27543504
4.

Pattern of Inflammation on Surveillance Colonoscopy Does Not Predict Development of Colitis-associated Neoplasia.

Jegadeesan R, Navaneethan U, Gutierrez NG, Venkatesh PG, Hammel JP, Sanaka MR, Shen B.

Inflamm Bowel Dis. 2016 Sep;22(9):2221-8. doi: 10.1097/MIB.0000000000000862.

PMID:
27542134
5.

Granulomonocytapheresis as a cell-based therapy in an ulcerative colitis patient complicated by aminosalicylate-induced severe lymphocytopenia and pneumonia.

Yokoyama Y, Kamikozuru K, Nakamura S.

Cytotherapy. 2016 Sep;18(9):1234-6. doi: 10.1016/j.jcyt.2016.05.016. No abstract available.

PMID:
27520926
6.

Gastroenterologists' Perceptions Regarding Ulcerative Colitis and Its Management: Results from a Large-Scale Survey.

Lasch K, Liu S, Ursos L, Mody R, King-Concialdi K, DiBonaventura M, Leberman J, Dubinsky M.

Adv Ther. 2016 Aug 10. [Epub ahead of print]

PMID:
27509887
7.

Golimumab for moderately to severely active ulcerative colitis.

Kedia S, Ahuja V, Makharia GK.

Expert Rev Clin Pharmacol. 2016 Aug 18:1-10. [Epub ahead of print]

PMID:
27498886
8.

Cost-utility analysis of 1-year treatment with adalimumab/standard care and standard care alone for ulcerative colitis in Poland.

Stawowczyk E, Kawalec P, Pilc A.

Eur J Clin Pharmacol. 2016 Aug 6. [Epub ahead of print]

PMID:
27497991
9.

Similar Clinical and Surgical Outcomes Achieved with Early Compared to Late Anti-TNF Induction in Mild-to-Moderate Ulcerative Colitis: A Retrospective Cohort Study.

Ma C, Beilman CL, Huang VW, Fedorak DK, Wong K, Kroeker KI, Dieleman LA, Halloran BP, Fedorak RN.

Can J Gastroenterol Hepatol. 2016;2016:2079582. doi: 10.1155/2016/2079582. Epub 2016 Jul 11.

10.

Diphenyl diselenide attenuates oxidative stress and inflammatory parameters in ulcerative colitis: A comparison with ebselen.

Petronilho F, Michels M, Danielski LG, Goldim MP, Florentino D, Vieira A, Mendonça MG, Tournier M, Piacentini B, Giustina AD, Leffa DD, Pereira GW, Pereira VD, Rocha JB.

Pathol Res Pract. 2016 May 2. pii: S0344-0338(16)30080-2. doi: 10.1016/j.prp.2016.04.012. [Epub ahead of print]

PMID:
27475409
11.

Sodium chloride-enriched diet enhances inflammatory cytokine production and exacerbates experimental colitis in mice.

Monteleone I, Marafini I, Dinallo V, Di Fusco D, Troncone E, Zorzi F, Laudisi F, Monteleone G.

J Crohns Colitis. 2016 Jul 29. pii: jjw139. [Epub ahead of print]

PMID:
27473029
12.

Clinical Characteristics of Ulcerative Colitis Complicated with Opportunistic Infections in Elderly Patients.

[No authors listed]

Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2016 Jun 10;38(3):288-93. doi: 10.3881/j.issn.1000-503X.2016.03.008.

13.

Genotype-Phenotype Associations of the CD-Associated Single Nucleotide Polymorphism within the Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 22 in Patients of the Swiss IBD Cohort.

Spalinger MR, Zeitz J, Biedermann L, Rossel JB, Sulz MC, Frei P, Scharl S, Vavricka SR, Fried M, Rogler G, Scharl M; Swiss IBD Cohort Study Group.

PLoS One. 2016 Jul 28;11(7):e0160215. doi: 10.1371/journal.pone.0160215. eCollection 2016.

14.
15.

Prognostic factors affecting early colectomy in patients with moderate to severe ulcerative colitis treated with calcineurin inhibitors.

Ban H, Bamba S, Nishida A, Inatomi O, Shioya M, Takahashi KI, Imaeda H, Murata M, Sasaki M, Tsujikawa T, Andoh A.

Exp Ther Med. 2016 Aug;12(2):829-834. Epub 2016 May 16.

16.

Granzyme M has a critical role in providing innate immune protection in ulcerative colitis.

Souza-Fonseca-Guimaraes F, Krasnova Y, Putoczki T, Miles K, MacDonald KP, Town L, Shi W, Gobe GC, McDade L, Mielke LA, Tye H, Masters SL, Belz GT, Huntington ND, Radford-Smith G, Smyth MJ.

Cell Death Dis. 2016 Jul 21;7:e2302. doi: 10.1038/cddis.2016.215.

PMID:
27441655
17.

Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies.

Adedokun OJ, Xu Z, Marano CW, Strauss R, Zhang H, Johanns J, Zhou H, Davis HM, Reinisch W, Feagan BG, Rutgeerts P, Sandborn WJ.

J Crohns Colitis. 2016 Jul 20. pii: jjw133. [Epub ahead of print]

PMID:
27440869
19.

Treatment of inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 2(nd) Asian Organization of Crohn's and Colitis (AOCC) meeting in Seoul.

Nakase H, Keum B, Ye BD, Park SJ, Koo HS, Eun CS.

Intest Res. 2016 Jul;14(3):231-9. doi: 10.5217/ir.2016.14.3.231. Epub 2016 Jun 27.

20.

Tacrolimus Exerts Only a Transient Effectiveness in Refractory Pediatric Crohn Disease: a Case Series.

Truffinet O, Martinez-Vinson C, Guerriero E, Hugot JP, Viala J.

J Pediatr Gastroenterol Nutr. 2016 Jul 16. [Epub ahead of print]

PMID:
27429426
Items per page

Supplemental Content

Loading ...
Write to the Help Desk